Identification of seven long noncoding RNAs signature for prediction of biochemical recurrence in prostate cancer

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2019,（6）
• 页码范围: 618-622
• 页数: 5页
• 语种: 英文
• DOI: 10.4103/aja.aja_118_18

摘要

Accumulating evidence suggested that long noncoding RNAs (IncRNAs) possess a potential role in prostate cancer (PCa) diagnosis and prognosis.Rapid biochemical recurrence (BCR) is considered as a sign for clinical recurrence metastasis and PCa-specific mortality.Hence,the aim of the present study was to identify a IncRNA signature that can predict BCR of PCa accurately.Bioinformatics analysis,Kaplan-Meier analyses,Cox regression analyses,and Gene Set Enrichment Analysis (GSEA) were performed in a publicly available database with 499 PCa tissues and 52 matched normal tissues.A signature was identified.All these IncRNAs were differentially expressed between tumor and normal tissues and differentially expressed between high Gleason score and low Gleason score tissues.Furthermore,we developed a seven IncRNAs signature that can predict PCa BCR.Patients classified into low-risk group showed better BCR survival significantly than the patients in the high-risk group (hazard ratio =0.32,95％ CI:0.20-0.52,concordance index =0.63).The area under the curve was 0.68 for BCR.The signature also had good discrimination for BCR in men with Gleason 7 PCa.In conclusion,our results suggest that the seven IncRNAssignature is a new biomarker of BCR and high risk in PCa.In addition,the individual IncRNA warrants further study to uncover the associated mechanisms of PCa progression and the signature could be used to design direct clinical trials for adjuvant therapy.